Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

BG Wortman; CL Creutzberg; H Putter; IM Jurgenliemk-Schulz; JJ Jobsen; L Lutgens; EM van de Steen-Banasik; Jan Willem Mens; A Slot; MCS Kroese; B van Triest; HW Nijman; E Stelloo; T Bosse; SM Boer; WLJ van Putten; V Smit; RA Nout

doi:10.1038/s41416-018-0310-8

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

BG Wortman, CL Creutzberg, H Putter, IM Jurgenliemk-Schulz, JJ Jobsen, L Lutgens, EM van de Steen-Banasik, Jan Willem Mens, A Slot, MCS Kroese, B van Triest, HW Nijman, E Stelloo, T Bosse, SM Boer, WLJ van Putten, V Smit, RA Nout

Radiotherapy

Research output: Contribution to journal › Article › Academic › peer-review

201 Citations (Scopus)

10 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	1067-1074
Number of pages	8
Journal	British Journal of Cancer
Volume	119
Issue number	9
DOIs	https://doi.org/10.1038/s41416-018-0310-8
Publication status	Published - 2018

Research programs

EMC MM-03-32-04

Access to Document

10.1038/s41416-018-0310-8

Repub_111672_O-A.pdfFinal published version, 774 KB

http://hdl.handle.net/1765/111672

Cite this

Wortman, BG., Creutzberg, CL., Putter, H., Jurgenliemk-Schulz, IM., Jobsen, JJ., Lutgens, L., van de Steen-Banasik, EM., Mens, J. W., Slot, A., Kroese, MCS., van Triest, B., Nijman, HW., Stelloo, E., Bosse, T., Boer, SM., van Putten, WLJ., Smit, V., & Nout, RA. (2018). Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. British Journal of Cancer, 119(9), 1067-1074. https://doi.org/10.1038/s41416-018-0310-8

@article{ef3b70533ded4fe999524ba9721abec4,

title = "Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy",

author = "BG Wortman and CL Creutzberg and H Putter and IM Jurgenliemk-Schulz and JJ Jobsen and L Lutgens and {van de Steen-Banasik}, EM and Mens, {Jan Willem} and A Slot and MCS Kroese and {van Triest}, B and HW Nijman and E Stelloo and T Bosse and SM Boer and {van Putten}, WLJ and V Smit and RA Nout",

year = "2018",

doi = "10.1038/s41416-018-0310-8",

language = "Undefined/Unknown",

volume = "119",

pages = "1067--1074",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "9",

}

Wortman, BG, Creutzberg, CL, Putter, H, Jurgenliemk-Schulz, IM, Jobsen, JJ, Lutgens, L, van de Steen-Banasik, EM, Mens, JW, Slot, A, Kroese, MCS, van Triest, B, Nijman, HW, Stelloo, E, Bosse, T, Boer, SM, van Putten, WLJ, Smit, V & Nout, RA 2018, 'Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy', British Journal of Cancer, vol. 119, no. 9, pp. 1067-1074. https://doi.org/10.1038/s41416-018-0310-8

TY - JOUR

T1 - Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

AU - Wortman, BG

AU - Creutzberg, CL

AU - Putter, H

AU - Jurgenliemk-Schulz, IM

AU - Jobsen, JJ

AU - Lutgens, L

AU - van de Steen-Banasik, EM

AU - Mens, Jan Willem

AU - Slot, A

AU - Kroese, MCS

AU - van Triest, B

AU - Nijman, HW

AU - Stelloo, E

AU - Bosse, T

AU - Boer, SM

AU - van Putten, WLJ

AU - Smit, V

AU - Nout, RA

PY - 2018

Y1 - 2018

U2 - 10.1038/s41416-018-0310-8

DO - 10.1038/s41416-018-0310-8

M3 - Article

C2 - 30356126

SN - 0007-0920

VL - 119

SP - 1067

EP - 1074

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 9

ER -